S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ESPR

Esperion Therapeutics Stock Competitors

$7.78
+0.09 (+1.17%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.21
$7.83
50-Day Range
$7.12
$12.92
52-Week Range
$6.97
$39.49
Volume
1.30 million shs
Average Volume
848,835 shs
Market Capitalization
$226.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9

Esperion Therapeutics (NASDAQ:ESPR) Vs. MCRB, ANAB, PAHC, OLMA, ARQT, KNTE, CELU, GOSS, SNDX, and KNSA

Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Seres Therapeutics (MCRB), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Olema Pharmaceuticals (OLMA), Arcutis Biotherapeutics (ARQT), Kinnate Biopharma (KNTE), Celularity (CELU), Gossamer Bio (GOSS), Syndax Pharmaceuticals (SNDX), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.

Esperion Therapeutics vs.

Esperion Therapeutics (NASDAQ:ESPR) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.

In the previous week, Esperion Therapeutics had 5 more articles in the media than AnaptysBio. MarketBeat recorded 5 mentions for Esperion Therapeutics and 0 mentions for AnaptysBio. Esperion Therapeutics' average media sentiment score of 0.25 beat AnaptysBio's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Esperion Therapeutics Neutral
AnaptysBio Neutral

Esperion Therapeutics received 240 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 71.38% of users gave Esperion Therapeutics an outperform vote while only 70.59% of users gave AnaptysBio an outperform vote.

CompanyUnderperformOutperform
Esperion TherapeuticsOutperform Votes
576
71.38%
Underperform Votes
231
28.62%
AnaptysBioOutperform Votes
336
70.59%
Underperform Votes
140
29.41%

AnaptysBio has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$227.55 million0.99-$143.55 million-$11.68-0.67
AnaptysBio$75 million11.41-$19.93 million$0.28111.14

Esperion Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

AnaptysBio has a net margin of 6.87% compared to Esperion Therapeutics' net margin of -424.39%. AnaptysBio's return on equity of 2.17% beat Esperion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Esperion Therapeutics -424.39% N/A -108.46%
AnaptysBio 6.87% 2.17% 2.02%

Esperion Therapeutics presently has a consensus price target of $40.36, suggesting a potential upside of 418.81%. AnaptysBio has a consensus price target of $35.50, suggesting a potential upside of 14.07%. Given Esperion Therapeutics' higher possible upside, equities analysts plainly believe Esperion Therapeutics is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Esperion Therapeutics
2 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.20
AnaptysBio
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

98.8% of Esperion Therapeutics shares are held by institutional investors. 7.3% of Esperion Therapeutics shares are held by insiders. Comparatively, 34.9% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

AnaptysBio beats Esperion Therapeutics on 10 of the 19 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Esperion Therapeutics (NASDAQ:ESPR) vs. Its Competitors

TypeEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$226.22M$5.93B$5.02B$7.85B
Dividend YieldN/A2.55%2.01%2.44%
P/E Ratio-0.6716.2023.4222.94
Price / Sales0.99560.062,473.12283.21
Price / CashN/A179.7571.84183.37
Price / Book-0.626.146.847.78
Net Income-$143.55M$96.94M$96.50M$154.07M
7 Day Performance4.99%-2.33%-2.79%-2.91%
1 Month Performance-12.09%-7.89%-7.68%-4.17%
1 Year Performance-71.21%19.33%21.43%32.45%

Esperion Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCRB
Seres Therapeutics
1.9769 of 5 stars
$9.35
+3.4%
$20.83
+122.8%
-67.8%$858.77M$33.22M-24.61155
ANAB
AnaptysBio
1.8664 of 5 stars
$31.12
+2.2%
$35.50
+14.1%
+20.7%$856.05M$75M111.1494
PAHC
Phibro Animal Health
2.7598 of 5 stars
$20.88
+5.4%
$23.00
+10.2%
+7.5%$845.72M$833.40M17.401,725Ex-Dividend
OLMA
Olema Pharmaceuticals
2.5333 of 5 stars
$20.87
+6.2%
$60.67
+190.7%
-58.1%$840.81MN/A-11.8637Short Interest ↑
ARQT
Arcutis Biotherapeutics
2.3865 of 5 stars
$16.67
+6.4%
$55.25
+231.4%
-35.7%$838.42MN/A-4.7254News Coverage
Gap Down
KNTE
Kinnate Biopharma
2.3667 of 5 stars
$19.12
+7.1%
$47.67
+149.3%
N/A$835.47MN/A0.0031Gap Down
CELU
Celularity
2.1333 of 5 stars
$6.75
+3.3%
$11.25
+66.7%
N/A$833.38MN/A0.00N/AAnalyst Report
GOSS
Gossamer Bio
2.4131 of 5 stars
$10.65
+5.6%
$22.50
+111.3%
+18.6%$814.34MN/A-3.27196Gap Down
SNDX
Syndax Pharmaceuticals
1.7606 of 5 stars
$16.48
+2.1%
$29.57
+79.4%
-27.9%$813.98M$1.52M-8.7743Options Volume
KNSA
Kiniksa Pharmaceuticals
2.1781 of 5 stars
$11.65
+4.1%
$29.00
+148.9%
-36.2%$802.55MN/A-4.55168Short Interest ↓
PGEN
Precigen
2.6064 of 5 stars
$3.86
+4.9%
$12.80
+231.6%
-48.5%$798.01M$103.18M-6.77194Insider Buying
Gap Down
IMGO
Imago BioSciences
1.7048 of 5 stars
$23.50
+0.5%
$32.00
+36.2%
N/A$787.93MN/A0.002,021Gap Down
RDUS
Radius Health
2.0164 of 5 stars
$16.53
+6.9%
$26.80
+62.1%
+2.8%$782.56M$238.65M-10.20310Short Interest ↓
News Coverage
Gap Down
ACRS
Aclaris Therapeutics
1.9398 of 5 stars
$12.62
+6.2%
$35.67
+182.6%
+280.1%$772.69M$6.48M-8.0959News Coverage
Gap Down
PNT
POINT Biopharma Global
1.1999 of 5 stars
$8.57
+0.6%
$12.50
+45.9%
N/A$772.35MN/A0.00N/AShort Interest ↑
DYN
Dyne Therapeutics
1.3932 of 5 stars
$14.71
+7.8%
N/A-26.1%$757.98MN/A-5.7747
PRAX
Praxis Precision Medicines
2.2 of 5 stars
$16.76
+9.8%
$36.50
+117.8%
-59.0%$751.79MN/A-4.842,020Gap Down
YMAB
Y-mAbs Therapeutics
2.3381 of 5 stars
$17.15
+3.4%
$49.33
+187.7%
-64.4%$748.50M$20.75M-18.44125Insider Selling
AKRO
Akero Therapeutics
2.0388 of 5 stars
$21.13
+5.0%
$51.86
+145.4%
-27.7%$737.18MN/A-7.4922Short Interest ↑
News Coverage
Gap Down
JANX
Janux Therapeutics
1.9315 of 5 stars
$17.66
+6.6%
$35.00
+98.2%
N/A$734.87MN/A0.0016Gap Down
CPRX
Catalyst Pharmaceuticals
2.5 of 5 stars
$7.10
+3.9%
$8.38
+18.0%
+91.9%$732.14M$119.07M18.2174
VBIV
VBI Vaccines
1.9917 of 5 stars
$2.78
+2.9%
$7.00
+151.8%
-4.1%$715.31M$1.06M-10.69130Analyst Downgrade
LXRX
Lexicon Pharmaceuticals
1.9714 of 5 stars
$4.74
+8.4%
$12.00
+153.2%
+192.6%$705.77M$24M-9.8878Gap Down
KDNY
Chinook Therapeutics
2.6248 of 5 stars
$15.38
+6.8%
$33.00
+114.6%
+9.9%$693.22M$830K-4.07105Positive News
Gap Down
KRON
Kronos Bio
2.4931 of 5 stars
$12.29
+6.6%
$36.00
+192.9%
-64.6%$692.51MN/A-5.3063News Coverage
Gap Down
AFMD
Affimed
2.3448 of 5 stars
$6.97
+1.4%
$12.71
+82.4%
+31.8%$685.06M$32.39M-12.67158Short Interest ↓
Analyst Revision
CARA
Cara Therapeutics
2.2917 of 5 stars
$12.80
+4.2%
$25.67
+100.5%
-14.4%$684.28M$135.08M26.1280
AVIR
Atea Pharmaceuticals
2.0331 of 5 stars
$8.14
+5.7%
$27.33
+235.8%
-76.4%$676.46M$48.63M0.0039
KZR
Kezar Life Sciences
1.4398 of 5 stars
$13.69
+3.3%
$17.00
+24.2%
+130.5%$672.81MN/A-13.6947Short Interest ↓
PRLD
Prelude Therapeutics
2.3331 of 5 stars
$14.00
+2.2%
$44.00
+214.3%
-70.6%$661.01MN/A-2.0768
SLN
Silence Therapeutics
1.825 of 5 stars
$22.00
+0.5%
$99.00
+350.0%
N/A$658.42M$5.48M0.0074Analyst Report
Short Interest ↑
News Coverage
High Trading Volume
ORMP
Oramed Pharmaceuticals
2.1583 of 5 stars
$20.21
+6.4%
$35.00
+73.2%
+354.2%$657.11M$2.71M-29.2912Upcoming Earnings
ZGNX
Zogenix
1.7598 of 5 stars
$11.70
+5.0%
$37.46
+220.2%
-45.7%$655.11M$13.64M-2.69218Gap Down
OGI
OrganiGram
1.7098 of 5 stars
$2.16
+0.0%
$4.04
+86.8%
+62.4%$647.66M$64.61M-4.24517Analyst Report
Short Interest ↑
Gap Down
SIGA
SIGA Technologies
0.6266 of 5 stars
$8.54
+3.9%
N/A+20.6%$632.95M$124.96M42.7042Analyst Downgrade
BTAI
BioXcel Therapeutics
1.9229 of 5 stars
$22.58
+5.6%
$97.29
+330.8%
-49.4%$631.79MN/A-5.6250
VERA
Vera Therapeutics
1.3798 of 5 stars
$30.00
+11.7%
$24.00
+20.0%
N/A$629.04MN/A0.0019Short Interest ↓
Gap Up
AMTI
Applied Molecular Transport
2.825 of 5 stars
$16.33
+16.3%
$80.33
+391.9%
-50.5%$628.54MN/A-7.2380News Coverage
Gap Down
PHAT
Phathom Pharmaceuticals
2.3665 of 5 stars
$19.80
+5.1%
$60.25
+204.3%
-54.1%$622.02MN/A-4.3855Gap Down
EGRX
Eagle Pharmaceuticals
2.2514 of 5 stars
$48.10
+4.4%
$51.00
+6.0%
+1.7%$621.16M$187.80M117.32106Analyst Upgrade
COLL
Collegium Pharmaceutical
2.1714 of 5 stars
$17.95
+3.2%
$25.33
+41.1%
-6.5%$620.51M$310.02M6.85234Short Interest ↑
VERU
Veru
2.1181 of 5 stars
$7.77
+1.5%
$19.60
+152.3%
+152.7%$620.47M$42.59M-776.22339Upcoming Earnings
Gap Down
FULC
Fulcrum Therapeutics
2.2998 of 5 stars
$15.06
+1.0%
$36.33
+141.3%
+30.5%$610.67M$8.82M-6.4173Short Interest ↑
EPIX
ESSA Pharma
2.0333 of 5 stars
$13.82
+1.0%
$34.67
+150.8%
+111.0%$607.86MN/A-14.2525Short Interest ↓
Analyst Revision
Gap Down
AMYT
Amryt Pharma
1.825 of 5 stars
$9.55
+2.8%
$29.50
+208.9%
-24.4%$607.38M$182.61M-19.902,020Analyst Report
Short Interest ↓
Analyst Revision
TBPH
Theravance Biopharma
2.1115 of 5 stars
$8.01
+5.5%
$10.88
+35.8%
-51.2%$590.32M$71.86M-2.33359News Coverage
Gap Down
PYR
PyroGenesis Canada
0 of 5 stars
$3.45
+0.9%
N/AN/A$589.25M$13.27M0.002,020Short Interest ↑
LGVN
Longeveron
0.3333 of 5 stars
$30.67
+37.9%
N/AN/A$586.44M$5.63M0.0012Gap Down
High Trading Volume
IMRX
Immuneering
1.6265 of 5 stars
$22.54
+6.6%
$43.67
+93.7%
N/A$584.71MN/A0.002,021Gap Down
ENOB
Enochian Biosciences
0.3333 of 5 stars
$10.98
+0.0%
N/A+289.4%$573.38MN/A0.0010Gap Down
This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.